Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib, Ruxolitinib, and Low Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma
NCT03773107Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib in multiple myeloma (MM) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03773107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773107.